134 related articles for article (PubMed ID: 35361043)
21. Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses.
Woopen C; Konofalska U; Akgün K; Ziemssen T
Front Immunol; 2022; 13():897748. PubMed ID: 35958567
[TBL] [Abstract][Full Text] [Related]
22. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
Arimura K; Tagaya E; Kikuchi K; Mitsuda T; Ebihara F; Maruyama T; Hamada Y; Unagami K; Kanzawa T; Sekiguchi H; Shimamoto K; Ishida H; Egawa H; Tanaka J; Kawana M
Transpl Immunol; 2023 Apr; 77():101777. PubMed ID: 36584927
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic monoclonal antibodies for COVID-19 management: an update.
Chavda VP; Prajapati R; Lathigara D; Nagar B; Kukadiya J; Redwan EM; Uversky VN; Kher MN; Patel R
Expert Opin Biol Ther; 2022 Jun; 22(6):763-780. PubMed ID: 35604379
[TBL] [Abstract][Full Text] [Related]
25. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
26. Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato Y; Yamamoto K; Nakaya Y; Morioka S; Takeuchi JS; Takamatsu Y; Maeda K; Kimura M; Sugiura W; Mitsuya H; Yano M; Ohmagari N
J Infect Chemother; 2022 Jul; 28(7):991-994. PubMed ID: 35337728
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes.
Hayek S; Ben-Shlomo Y; Dagan N; Reis BY; Barda N; Kepten E; Roitman A; Shapira S; Yaron S; Balicer RD; Netzer D; Peretz A
Nat Commun; 2022 Aug; 13(1):4480. PubMed ID: 35918340
[TBL] [Abstract][Full Text] [Related]
28. Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis.
Kakinoki Y; Yamada K; Tanino Y; Suzuki K; Ichikawa T; Suzuki N; Asari G; Nakamura A; Kukita S; Uehara A; Saito S; Kuroda S; Sakagami H; Nagashima Y; Takahashi K; Suzuki S
Int J Infect Dis; 2022 Apr; 117():189-194. PubMed ID: 35176486
[TBL] [Abstract][Full Text] [Related]
29. An update of antispike severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies.
Chatterjee S; Choudhury S; Das D
Indian J Pharmacol; 2022; 54(1):51-57. PubMed ID: 35343208
[TBL] [Abstract][Full Text] [Related]
30. Advances in the Omicron variant development.
Vitiello A; Ferrara F; Auti AM; Di Domenico M; Boccellino M
J Intern Med; 2022 Jul; 292(1):81-90. PubMed ID: 35289434
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Coronavirus Disease 2019 (COVID-19).
Mayer C; VanHise K; Caskey R; Naqvi M; Burwick RM
Obstet Gynecol; 2021 Dec; 138(6):937-939. PubMed ID: 34583385
[TBL] [Abstract][Full Text] [Related]
32. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
[TBL] [Abstract][Full Text] [Related]
33. Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial.
Portal-Celhay C; Forleo-Neto E; Eagan W; Musser BJ; Davis JD; Turner KC; Norton T; Hooper AT; Hamilton JD; Pan C; Mahmood A; Baum A; Kyratsous CA; Kim Y; Parrino J; Kampman W; Roque-Guerrero L; Stoici R; Fatakia A; Soo Y; Geba GP; Kowal B; DiCioccio AT; Stahl N; Lipsich L; Braunstein N; Herman GA; Yancopoulos GD; Weinreich DM;
JAMA Netw Open; 2022 Aug; 5(8):e2225411. PubMed ID: 35969402
[TBL] [Abstract][Full Text] [Related]
34. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
Bierle DM; Ganesh R; Razonable RR
J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
[TBL] [Abstract][Full Text] [Related]
35. COVID-19 Therapeutics and Vaccines: A Race to Save Lives.
Bebenek I; Bannister R; Dubinion J; Fortin M; Liu M; Motter AL; Rohde CM; Wrzesinski C
Toxicol Sci; 2022 Jan; 185(2):119-127. PubMed ID: 34735018
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.
Jovanoski N; Kuznik A; Becker U; Hussein M; Briggs A
J Manag Care Spec Pharm; 2022 May; 28(5):555-565. PubMed ID: 35238626
[No Abstract] [Full Text] [Related]
37. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
[TBL] [Abstract][Full Text] [Related]
38. Timing of REGEN-COV administration and progression to severe COVID-19.
Kadowaki T; Imajou S; Matsumoto N; Takao S; Yorifuji T
J Infect Chemother; 2022 Nov; 28(11):1459-1463. PubMed ID: 35817250
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
[No Abstract] [Full Text] [Related]
40. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
Parums DV
Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
